Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01222117 · ClinicalTrials.gov registry record · Phase 2
A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion
A Phase 2 study, sponsored by Grifols Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 174
- Enrollment target
NCT01222117: Completed Phase 2 study, sponsored by Grifols Therapeutics.
NCT01222117 is a Phase 2 study that has completed, run by Grifols Therapeutics. The registered enrollment target is 174 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (31% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01222117, a Phase 2 study, has completed, sponsored by Grifols Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 174 participants
- Enrollment target
Study Summary
The primary purpose of this Phase 2 study is to optimize Plasmin delivery by comparing different delivery regimens in patients with peripheral arterial occlusion. The study includes a blinded plasminogen activator treatment group and a blinded plasminogen activator placebo group. The study will also assess safety and tolerability of Plasmin at 150 and 250 mg doses.
Primary Outcome
The proportion of subjects with \>50% thrombolysis at the end of treatment compared to baseline by arteriography.
Interventions
- OTHER Placebo
- BIOLOGICAL Plasmin
- BIOLOGICAL Plasminogen Activator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2010-12 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
What the finished NCT01222117 record still lists
NCT01222117 is an interventional study that assigns participants to a tested intervention. The registered 174 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (31% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01222117 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01222117 about?
NCT01222117 is a clinical study titled "A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion". The primary purpose of this Phase 2 study is to optimize Plasmin delivery by comparing different delivery regimens in patients with peripheral arterial occlusion. The study includes a blinded plasminogen activator treatment group and a blinded plasminogen activator placebo group. The study will also...
What is the current status of trial NCT01222117?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 174 participants. The study started on 2010-12. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01222117?
The interventions under investigation include: Placebo (OTHER), Plasmin (BIOLOGICAL), Plasminogen Activator (BIOLOGICAL).
Who is sponsoring clinical trial NCT01222117?
This trial is sponsored by Grifols Therapeutics, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01222117's enrollment target sits among peer trials
174 396th of 2000 higher than 1,604 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01000259 · 174 participants
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
- NCT04729114 · 174 participants · Phase 1
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
- NCT04884035 · 174 participants · Phase 1
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
- NCT05075980 · 174 participants · Phase 2
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia